Instem Share Discussion Threads

[brummy_git] 29/4/2017 07:49

p1nkfish - Have you ever met the CEO and FD? If so, what do you think of them?

[p1nkfish] 28/4/2017 23:01

I do enjoy a quiet pbb, especially when a large investor repeatedly ups their holding in an otherwise unloved company with small float.

[p1nkfish] 26/4/2017 09:46

RNS to confirm revenue and profit for below from March 28th results will be recognised in the current FY. Now we know!

"We are pleased to report that the order expanding the utilisation of Provantis at the US National Institute of Environmental Health Sciences ("NIEHS"), delayed from 2016, has recently been received and the appropriate accounting treatment for revenue and profit recognition purposes is currently being assessed."

[p1nkfish] 17/4/2017 17:40

Where the US goes, we go. Healthcare one of the few sectors showing some potential upside vs downside.

[p1nkfish] 04/2/2017 23:28

So much for the share event.
At least approaching buy zone again.

[sharesevents] 19/1/2017 15:08

Promotional post - The Growth and Innovation Forum will show you how to take advantage of new investment opportunities in technology stocks and funds. Come and see Terry Hart, CFO – CityFibre and 20 other companies present at the Growth and Innovation Forum on 31st January 2017 at Business Design Centre London. Find the next stock market ‘winner’. Satellite Solutions Worldwide +79%, CyanConnode +43%, Instem + 44%, Summit Therapeutics +32% and XLMedia +46% all attended last year. Click to register to attend for free

The other companies also presenting Jaywing, RedstoneConnect, Blancco Technology Group, CloudCall, Frontier IP Group, CyanConnode, Bango, LoopUp, CityFibre, TP Group, AJ Bell, ANGLE, Legal & General UK Alpha Trust, Defenx, Instem, WANdisco, Collagen Solutions, Avacta, One pm Finance, Cenkos Securities and Mirada.

[p1nkfish] 16/1/2017 10:04

I think run to 260p possible in short order.

[p1nkfish] 16/1/2017 10:03

Nothing to be concerned about on the update and the delayed orders to £1.2M should land 2017. Net cash increase of £1.9M

"Importantly, the overall market dynamics for our products and services remains positive and we therefore look forward to the next financial year with increasing optimism."

Increasing optimism - interesting.

[p1nkfish] 21/12/2016 20:50

Logos man sold out. Any price sub £2 is a bargain.

[p1nkfish] 15/12/2016 22:26

Look on the bright side, £700k less paid out but better if the acquisition had performed.

[p1nkfish] 21/11/2016 12:03

I'm still in the money on INS but have also decided to add a fair few.
I also see this as not a showstopper, just a trip on the way to the stage.

[p1nkfish] 21/11/2016 07:42

Looking at the price graph above who said info doesn't leak if that price move is from last Friday (I didn't check)?

Hold - these are delays and the foundations are still sound and the 2017 looking to have not been harmed.

[p1nkfish] 29/10/2016 02:06

Sbs went private.
Crx likely to be acquired.
Who next?

[p1nkfish] 06/9/2016 17:19

Pleasing to see this rise. Not many of us here so all the best whoever is on the same raft.I hold crx, held sbs, hold odx. A useful UK biotechnology grouping with ins.

[proactivest] 25/8/2016 11:56

Video interview with Phil Reason



Instem PLC (LON:INS) chief executive Phil Reason tells Proactive Investors that the company wants to “dominate” niche markets after it announced a solid first six months of trading in 2016.
“We think we can do as we do in many other areas of our business and be a market leader in a particular niche,” Reason says.
“We have some particular areas where we think we can dominate some of those niches.”
Reason adds that the biotech industry, the company’s main market, has been “buoyant” for the last couple of years and he expects it to remain that way for the foreseeable future.
“The contact research organisations that make up a lot of our client base today, their facilities are generally full as they conduct probably the largest numbers of studies they’ve ever enjoyed.”

[wjccghcc] 16/8/2016 11:55

Yup. One of my larger holdings.

[p1nkfish] 16/8/2016 11:50

Anyone else here. As bio turns round I expect this to move up a gear. Steady as she goes in the meantime.

[p1nkfish] 31/5/2016 23:02

Sensible looking acquisition.

[proactivest] 05/4/2016 15:40

Video interview with Nigel Goldsmith



Nigel Goldsmith, chief financial officer of Instem PLC (LON:INS) tells Proactive the firm had an “exceptionally good year in 2015”, which has given it a “very strong platform” for this year.
The company, which develops software used in clinical trials, recorded significant year-on-year growth in 2015 as its main markets continue to expand. Revenues increased by 22% in the 12 months to December 31 to £16.3mln, £10mln of which were recurring.
Instem also increased its cash reserves, and Goldsmith says this, combined with a £5mln fundraise, will allow the company to look at “new acquisitions” in a “fragmented sector” with “lots of opportunities”.

[brummy_git] 15/1/2016 11:49

p1nkfish - is there any link to Instem wrt your posted Telegraph article?

[wjccghcc] 15/1/2016 11:48

And this has what to do with Instem? They provide software for managing data for preclinical and early stage clinical drugs. Nothing to do with the drugs themselves.